Annual Cash & Cash Equivalents
$3.95 M
+$2.87 M+266.17%
December 31, 2024
Summary
- As of March 6, 2025, GTBP annual cash & cash equivalents is $3.95 million, with the most recent change of +$2.87 million (+266.17%) on December 31, 2024.
- During the last 3 years, GTBP annual cash & cash equivalents has fallen by -$5.02 million (-55.94%).
- GTBP annual cash & cash equivalents is now -55.94% below its all-time high of $8.97 million, reached on December 31, 2021.
Performance
GTBP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.95 M
-$2.47 M-38.44%
December 31, 2024
Summary
- As of March 6, 2025, GTBP quarterly cash and cash equivalents is $3.95 million, with the most recent change of -$2.47 million (-38.44%) on December 31, 2024.
- Over the past year, GTBP quarterly cash and cash equivalents has dropped by -$2.47 million (-38.44%).
- GTBP quarterly cash and cash equivalents is now -90.00% below its all-time high of $39.51 million, reached on June 30, 2021.
Performance
GTBP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GTBP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +266.2% | -38.4% |
| 3 y3 years | -55.9% | +93.2% |
| 5 y5 years | +10000.0% | +93.2% |
GTBP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.9% | +266.2% | -57.3% | +266.2% |
| 5 y | 5-year | -55.9% | >+9999.0% | -90.0% | >+9999.0% |
| alltime | all time | -55.9% | >+9999.0% | -90.0% | -100.0% |
GT Biopharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $3.95 M(+266.2%) | $3.95 M(-38.4%) |
| Sep 2024 | - | $6.42 M(-30.6%) |
| Jun 2024 | - | $9.25 M(+374.3%) |
| Mar 2024 | - | $1.95 M(+80.7%) |
| Dec 2023 | $1.08 M(-81.0%) | $1.08 M(-59.3%) |
| Sep 2023 | - | $2.65 M(-4.3%) |
| Jun 2023 | - | $2.77 M(+35.3%) |
| Mar 2023 | - | $2.04 M(-63.9%) |
| Dec 2022 | $5.67 M(-36.8%) | $5.67 M(+130.1%) |
| Sep 2022 | - | $2.46 M(-54.0%) |
| Jun 2022 | - | $5.36 M(-26.5%) |
| Mar 2022 | - | $7.29 M(-18.8%) |
| Dec 2021 | $8.97 M(+69.3%) | $8.97 M(-7.4%) |
| Sep 2021 | - | $9.68 M(-75.5%) |
| Jun 2021 | - | $39.51 M(+43.4%) |
| Mar 2021 | - | $27.55 M(+420.2%) |
| Dec 2020 | $5.30 M(>+9900.0%) | $5.30 M(+1413.4%) |
| Sep 2020 | - | $350.00 K(-58.9%) |
| Jun 2020 | - | $851.00 K(>+9900.0%) |
| Mar 2020 | - | $5000.00(-82.1%) |
| Dec 2019 | $28.00 K(-53.3%) | $28.00 K(-91.1%) |
| Sep 2019 | - | $313.00 K(+18.6%) |
| Jun 2019 | - | $264.00 K(+417.6%) |
| Mar 2019 | - | $51.00 K(-15.0%) |
| Dec 2018 | $60.00 K(-89.6%) | $60.00 K(-95.1%) |
| Sep 2018 | - | $1.23 M(+12.4%) |
| Jun 2018 | - | $1.10 M(-61.8%) |
| Mar 2018 | - | $2.87 M(+398.3%) |
| Dec 2017 | $576.00 K(+2931.6%) | $576.00 K(-78.9%) |
| Sep 2017 | - | $2.73 M(+6905.1%) |
| Jun 2017 | - | $39.00 K(-83.4%) |
| Mar 2017 | - | $235.00 K(+1136.8%) |
| Dec 2016 | $19.00 K(-59.6%) | $19.00 K(-87.7%) |
| Sep 2016 | - | $154.00 K(-56.6%) |
| Jun 2016 | - | $355.00 K(+1083.3%) |
| Mar 2016 | - | $30.00 K(-36.2%) |
| Dec 2015 | $47.00 K(-94.5%) | $47.00 K(+11.9%) |
| Sep 2015 | - | $42.00 K(-66.4%) |
| Jun 2015 | - | $125.00 K(-91.2%) |
| Mar 2015 | - | $1.42 M(+65.8%) |
| Dec 2014 | $855.00 K(+1888.4%) | $855.00 K(+28.8%) |
| Sep 2014 | - | $664.00 K(>+9900.0%) |
| Jun 2014 | - | $1000.00(-75.0%) |
| Mar 2014 | - | $4000.00(-90.7%) |
| Dec 2013 | $43.00 K(-65.0%) | $43.00 K(>+9900.0%) |
| Sep 2013 | - | $0.00(-100.0%) |
| Jun 2013 | - | $11.00 K(>+9900.0%) |
| Mar 2013 | - | $0.00(-100.0%) |
| Dec 2012 | $123.00 K(+33.7%) | $123.00 K(+101.6%) |
| Sep 2012 | - | $61.00 K(+1120.0%) |
| Jun 2012 | - | $5000.00(-95.8%) |
| Mar 2012 | - | $120.00 K(+30.4%) |
| Dec 2011 | $92.00 K(+70.4%) | $92.00 K(>+9900.0%) |
| Sep 2011 | - | $0.00(-100.0%) |
| Jun 2011 | - | $89.00 K(+8800.0%) |
| Mar 2011 | - | $1000.00(-98.1%) |
| Dec 2010 | $54.00 K(-95.8%) | $54.00 K(-70.2%) |
| Sep 2010 | - | $181.00 K(-68.3%) |
| Jun 2010 | - | $571.00 K(-32.0%) |
| Mar 2010 | - | $840.00 K(-35.0%) |
| Dec 2009 | $1.29 M(+5777.3%) | $1.29 M(>+9900.0%) |
| Sep 2009 | - | $0.00(-100.0%) |
| Jun 2009 | - | $44.00 K(>+9900.0%) |
| Mar 2009 | - | $0.00(-100.0%) |
| Dec 2008 | $22.00 K(-98.1%) | $22.00 K(-29.0%) |
| Sep 2008 | - | $31.00 K(-86.6%) |
| Jun 2008 | - | $232.00 K(-78.3%) |
| Mar 2008 | - | $1.07 M(-6.3%) |
| Dec 2007 | $1.14 M | $1.14 M(-28.3%) |
| Sep 2007 | - | $1.59 M(+31.7%) |
| Jun 2007 | - | $1.21 M(+1.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2007 | - | $1.19 M(-1.2%) |
| Dec 2006 | $1.21 M(+96.7%) | $1.21 M(+78.4%) |
| Sep 2006 | - | $677.00 K(+46.9%) |
| Jun 2006 | - | $461.00 K(-35.9%) |
| Mar 2006 | - | $719.00 K(+17.1%) |
| Dec 2005 | $614.00 K(-86.9%) | $614.00 K(-84.0%) |
| Sep 2005 | - | $3.85 M(-13.6%) |
| Jun 2005 | - | $4.45 M(-10.6%) |
| Mar 2005 | - | $4.98 M(+6.3%) |
| Dec 2004 | $4.69 M(+1159.9%) | $4.69 M(+496.3%) |
| Sep 2004 | - | $786.00 K(-29.5%) |
| Jun 2004 | - | $1.11 M(+262.0%) |
| Mar 2004 | - | $308.00 K(-17.2%) |
| Dec 2003 | $372.00 K(-12.3%) | $372.00 K(+56.3%) |
| Sep 2003 | - | $238.00 K(+38.4%) |
| Jun 2003 | - | $172.00 K(-53.6%) |
| Mar 2003 | - | $371.00 K(-12.5%) |
| Dec 2002 | $424.00 K(+91.9%) | $424.00 K(-12.8%) |
| Sep 2002 | - | $486.00 K(-48.0%) |
| Jun 2002 | - | $934.00 K(-21.4%) |
| Mar 2002 | - | $1.19 M(+438.0%) |
| Dec 2001 | $221.00 K(-89.3%) | $221.00 K(-14.3%) |
| Sep 2001 | - | $258.00 K(-44.2%) |
| Jun 2001 | - | $462.00 K(-55.6%) |
| Mar 2001 | - | $1.04 M(-49.4%) |
| Dec 2000 | $2.06 M(+161.0%) | $2.06 M(-35.7%) |
| Sep 2000 | - | $3.20 M(-29.8%) |
| Jun 2000 | - | $4.56 M(+8.5%) |
| Mar 2000 | - | $4.21 M(+433.0%) |
| Dec 1999 | $789.00 K(-69.7%) | $789.00 K(+294.5%) |
| Sep 1999 | - | $200.00 K(-81.8%) |
| Jun 1999 | - | $1.10 M(-26.7%) |
| Mar 1999 | - | $1.50 M(-42.3%) |
| Dec 1998 | $2.60 M(+100.0%) | $2.60 M(-36.6%) |
| Sep 1998 | - | $4.10 M(+24.2%) |
| Jun 1998 | - | $3.30 M(+725.0%) |
| Mar 1998 | - | $400.00 K(-69.2%) |
| Dec 1997 | $1.30 M(+225.0%) | $1.30 M(-53.6%) |
| Sep 1997 | - | $2.80 M(-33.3%) |
| Jun 1997 | - | $4.20 M(+1300.0%) |
| Mar 1997 | - | $300.00 K(-25.0%) |
| Dec 1996 | $400.00 K(-42.9%) | $400.00 K(+300.0%) |
| Sep 1996 | - | $100.00 K(-90.9%) |
| Jun 1996 | - | $1.10 M(+22.2%) |
| Mar 1996 | - | $900.00 K(+28.6%) |
| Dec 1995 | $700.00 K(-22.2%) | $700.00 K(-30.0%) |
| Sep 1995 | - | $1.00 M(-9.1%) |
| Jun 1995 | - | $1.10 M(+57.1%) |
| Mar 1995 | - | $700.00 K(-22.2%) |
| Dec 1994 | $900.00 K(+12.5%) | $900.00 K(+12.5%) |
| Sep 1994 | - | $800.00 K(-27.3%) |
| Jun 1994 | - | $1.10 M(-8.3%) |
| Mar 1994 | - | $1.20 M(+50.0%) |
| Dec 1993 | $800.00 K(+166.7%) | $800.00 K(+14.3%) |
| Sep 1993 | - | $700.00 K(-22.2%) |
| Jun 1993 | - | $900.00 K(+200.0%) |
| Mar 1993 | - | $300.00 K(0.0%) |
| Dec 1992 | $300.00 K(0.0%) | $300.00 K(+200.0%) |
| Sep 1992 | - | $100.00 K(-50.0%) |
| Jun 1992 | - | $200.00 K(-33.3%) |
| Mar 1992 | - | $300.00 K(0.0%) |
| Dec 1991 | $300.00 K(-93.6%) | $300.00 K(+200.0%) |
| Sep 1991 | - | $100.00 K(-97.9%) |
| Dec 1990 | $4.70 M(+30.6%) | $4.70 M(+30.6%) |
| Dec 1989 | $3.60 M(+38.5%) | $3.60 M(+38.5%) |
| Dec 1988 | $2.60 M(+8.3%) | $2.60 M(+8.3%) |
| Dec 1987 | $2.40 M(0.0%) | $2.40 M(0.0%) |
| Dec 1986 | $2.40 M(+33.3%) | $2.40 M(+33.3%) |
| Dec 1985 | $1.80 M(-33.3%) | $1.80 M(-33.3%) |
| Dec 1984 | $2.70 M(+17.4%) | - |
| Dec 1984 | - | $2.70 M |
| Feb 1984 | $2.30 M | - |
FAQ
- What is GT Biopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for GT Biopharma?
- What is GT Biopharma annual cash & cash equivalents year-on-year change?
- What is GT Biopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for GT Biopharma?
- What is GT Biopharma quarterly cash and cash equivalents year-on-year change?
What is GT Biopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of GTBP is $3.95 M
What is the all time high annual cash & cash equivalents for GT Biopharma?
GT Biopharma all-time high annual cash & cash equivalents is $8.97 M
What is GT Biopharma annual cash & cash equivalents year-on-year change?
Over the past year, GTBP annual cash & cash equivalents has changed by +$2.87 M (+266.17%)
What is GT Biopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GTBP is $3.95 M
What is the all time high quarterly cash and cash equivalents for GT Biopharma?
GT Biopharma all-time high quarterly cash and cash equivalents is $39.51 M
What is GT Biopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, GTBP quarterly cash and cash equivalents has changed by -$2.47 M (-38.44%)